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Abstract
Purpose: IFNa was the first cytokine to demonstrate anti-tumor activity in advanced melanoma. Despite the ability of high-
dose IFNa reducing relapse and mortality by up to 33%, large majority of patients experience side effects and toxicity which
outweigh the benefits. The current study attempts to identify genetic markers likely to be associated with benefit from IFN-
a2b treatment and predictive for survival.
Experimental design: We tested the association of variants in FOXP3 microsatellites, CTLA4 SNPs and HLA genotype in 284
melanoma patients and their association with prognosis and survival of melanoma patients who received IFNa adjuvant
therapy.
Results: Univariate survival analysis suggested that patients bearing either the DRB1*15 or HLA-Cw7 allele suffered worse
OS while patients bearing either HLA-Cw6 or HLA-B44 enjoyed better OS. DRB1*15 positive patients suffered also worse RFS
and conversely HLA-Cw6 positive patients had better RFS. Multivariate analysis revealed that a five-marker genotyping
signature was prognostic of OS independent of disease stage. In the multivariate Cox regression model, HLA-B38 (p = 0.021),
HLA-C15 (p = 0.025), HLA-C3 (p = 0.014), DRB1*15 (p = 0.005) and CT60*G/G (0.081) were significantly associated with OS
with risk ratio of 0.097 (95% CI, 0.013–0.709), 0.387 (95% CI, 0.169–0.889), 0.449 (95% CI, 0.237–0.851), 1.948 (95% CI, 1.221–
3.109) and 1.484 (95% IC, 0.953–2.312) respectively.
Conclusion: These results suggest that gene polymorphisms relevant to a biological occurrence are more likely to be
informative when studied in concert to address potential redundant or conflicting functions that may limit each gene
individual contribution. The five markers identified here exemplify this concept though prospective validation in
independent cohorts is needed.
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Introduction
The incidence of melanoma in the US increased threefold in the
past 3 decades [1] and an estimated 114,900 new cases were
diagnosed in 2010; among them, 46,770 were noninvasive (in situ)
while 68,130 were invasive resulting in 8,700 deaths [2]. The
survival of patients, whose melanoma is detected early, is about 99
percent [3] and a 5 year survival of around 95% for stage I tumors
[4]. However, the survival rate falls to 15 percent for those with
advanced disease [5].
Interferon alpha (IFN-a) was the first cytokine to demonstrate
anti-tumor activity in patients with advanced melanoma and is the
only approved regimen for the adjuvant treatment for melanoma.
Despite the ability of high dose IFN-a to reduce relapse and
mortality by up to 33% [6], the large majority of patients
experience side effects and toxicity which outweigh the benefits.
Attempts to identify a subset of patients likely to benefit from
adjuvant treatment with IFN-a2b have failed to discover clinical
or demographic features of true predictive value. Correlative
studies undertaken over the years identified a variety of
immunologic parameters that are associated with therapeutic
benefit but are observable only after therapy and, therefore, have
no predictive value [7,8]. Recently, mounting evidence indicates
that immune cell infiltration in tumor correlates with prolonged
survival suggesting a fine balance between tumor progression and
immune recognition within the tumor microenvironment. This
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balance relies on multiple factors important for the maintenance of
normal immune function. Among them, human leukocyte antigen
(HLA), Cytotoxic T lymphocyte antigen 4 (CTLA4) and FOXP3,
a member of the fork head/winged-helix family of transcriptional
regulators are important first and secondary signal molecules
influencing T lymphocyte activation and function. HLA genotype
has been associated with disease susceptibility, immune respon-
siveness and prognosis [9,10]. Single nucleotide polymorphisms
(SNPs) in the CTLA4 and microsatellite polymorphism in FOXP3
gene region were also reported to be associated with several
autoimmune diseases including, type-1 diabetes, systemic lupus
erythematosus, autoimmune thyroid diseases and celiac disease
[10–16]. Based on the observation that allelic polymorphism of
individual genes is generally only weakly associated with disease
predisposition in multi-genic disorders like cancer, a multi-factorial
contribution by distinct genes affecting a specific function (i.e. T
cell function) could be hypothesized; thus, polymorphisms of
CTLA4, FOXP3 and HLA genes in melanoma patients may
contribute to variability in patient survival and prognosis and their
combination may have stronger predictive power than that of each
genes assessed as a single entity. Thus, we tested the association of
variants in FOXP3 microsatellites, CTLA4 SNPs and HLA
genotype in 284 melanoma patients and their association with
prognosis and survival of patients with melanoma who received
adjuvant therapy with IFNa.
Materials and Methods
Study Subjects
The present translational research protocol was approved by the
Bioethics Committee of the National and Kapodistrian University
of Athens School of Medicine, Ethics Committee of Athens
General Hospital ‘‘G. Gennimatas’’, under the general title
‘‘Immunological studies of melanoma patients receiving adjuvant
interferon’’ (A399/5-3-1999). Patients participating in this study
were enrolled in Trial 13A/98, a prospective, multicenter,
randomized phase III trial conducted at 13 institutions by the
Hellenic Cooperative Oncology Group (HeCOG). In this trial,
364 patients with histologically documented AJCC stage IIB, IIC,
or III primary cutaneous melanoma were enrolled between 1998
and 2004. For patients with clinically negative lymph nodes, stage
was defined pathologically by sentinel lymph node (SLN) biopsy.
Patients with positive SLN were required to undergo completion
lymphadenectomy. All patients were randomized to receive
treatment within 2 months of initial surgery or 1.5 months
following therapeutic lymph node dissection. The regimen used
was a modification of the E1684 regimen [17]. Group A patients
received IFN-a2b (15 MIU/m2/day IV 5 days per week for 4
weeks) followed by observation. Group B patients received the
same induction dose for 4 weeks followed by subcutaneous therapy
(10 MIU/day TIW) for an additional 48 weeks. The primary
endpoint for the core protocol was recurrence free survival (RFS)
and overall survival (OS) and no difference in relapse free survival,
distant metastasis free survival or overall survival was shown
between the 2 groups [17].
The polymorphism study reported here was conducted retro-
spectively in four institutions that had participated in the core
protocol. This study received separate IRB approval, and all
patients had provided written informed consent for provision of
biological material for such future research studies at initiation of
treatment. Blood samples for CTLA-4, FOXP3 and HLA typing
were drawn prior to treatment at the time of routine initial visit
blood testing. The first 10 mL of blood were used for standard
biochemistry and blood cell counts, and the second 3 mL were
used for polymorphism testing. DNA was isolated using the
BioRobotH EZ1 Genomic DNA Kit and (GenoVision, Oslo,
Norway). The clinical outcome of patients was prospectively
followed according to standard parameters; clinical staging
consisted of medical history, physical exams, blood cell counts,
blood biochemistry at 3-month intervals, and chest x-ray and liver
ultrasound at 6-month intervals. Out of 364 patients, 284 were
genotyped for all three genes assessed in the current study based
on available DNA samples.
Selection of Single Nucleotide Polymorphisms in the
Human CTLA4 Gene and Microsatellite in FOXP3 Gene
Six CTLA4 SNPs, CT 60, AG 49, CT 318, JO 27, JO 30 and
JO 31 were selected based on known association with autoimmune
disorders [18–22]. CT 318 is located within the promoter region
of the CTLA-4 gene, A/G49 is located at exon 1, while the rest of
the SNPs are located at the 39 untranslated region of CTLA-4
[22].
Microsatellite (TC)n of FOXP3 located within intron 5 from
+476 to +595, up to +539 (IVS5) on Xp11.23 was selected based
on previous publication and tested by using the previously
described PCR primer pairs for primer sequences and nomencla-
ture [14].
Polymorphism Detection
HLA typing was performed using previously published DNA
based techniques [23–25]. Initially HLA-A,-B,-Cw,-DRB1,and -
DQB1 low resolution molecular typing was performed in all
subjects, with amplification of genomic DNA by polymerase chain
reaction (PCR) using locus-specific primers and reverse hybrid-
ization with sequence and allele-specific oligonucleotide probes
(reverse PCR-SOP), using a commercially available kit (Lambda
Array Beads Multi-Analyte System, LABTypeH RSS0, One
Lambda, Inc). Subsequently, high resolution typing of HLA-
DRB1 and -DQB1 loci was implemented by sequence specific
oligonucleotide (SSO) (ELPHA HiRes, Biotest, Germany) and
sequence specific primer (SSP) PCR (Olerup SSPTM, Salt-
sjoebaden, Sweden) respectively. The allele assignment was made
according to the HLA-visual software program.
FOXP3 (TC)n microsatellite analysis was performed by capillary
electrophoresis using DNA isolated from 259 patients. PCR
amplification was conducted using (TC)n forward primer and
reverse primer (Table 1). The reaction mixture were denatured at
95uC for 15 minutes and cycled 35 times at 94uC for 30 second,
54uC for 30 second and 72uC for 30 second followed by 72uC for
30 min. After digestion with EXOSAP at 37uC for 15 min and
80uC for 15 min to remove unincorporated primers and inactivate
the enzyme, the PCR product mixed with internal size standard
(Gene Scan-350) and formamide were analyzed by ABI Prism
3730 XL DNA analyzer. Data were analyzed using Genemapper
software (Applied Biosystems) which automatically calls fragments
size.
CTLA4 SNP-PCR was carried out with the primer pairs
listed in Table 1. 50 ng of DNA were amplified in a 50 mL
reaction containing 25 mL MasterMix (Illustra HotStart Mas-
terMix, GE Healthcare, Buckinghamshire, UK) 1 mL (10 pmol)
of each primer and nuclease free water. PCR were denatured at
5 minute at 95uC followed by 45 cycles of 95uC for15 seconds,
30 seconds at 56uC and 15 seconds at 72uC followed by final
extension at 72uC for 5 minutes. The single strand PCR
products were prepared by Streptavidin SepharoseTM High
Performance beads capture (GE Healthcare, Uppsala, Sweden)
after denaturation and washing (Biotage, Uppsala, Sweden)
according to manual. All sequencing reactions were performed
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on the PyroMarkTM ID pyrosequencer, using the PSQ 96 SNP
Reagent Kit (Biotage AB), under sequence primer (Table 1) and
analysis was done with PyroMarkTM ID 1.0 software.
Data Processing and Statistic Analysis
Variable coding. For HLA alleles, each patient was counted
as an event and a given allele was coded as 1 if detected either in
heterozygous or homozygous conditions or 0 if undetected. For
each allele, an additional code classified as 1 for homozygosity and
0 for heterozygosity. For CTLA-4 and FOXP3 testing, each
patient was counted as an unique event and a particular allele was
coded as 1 if detected or 0 if undetected. Of all potential variant
alleles only those presented at least with a frequency of 10%, i.e., a
total of 71 variables were included in the analysis.
Feature selection and prediction models. OS and RFS
were calculated from the date treatment was started to the date of
last follow-up or the date when death from any cause or relapse
first occurred. We first performed univariate analysis to identify
markers (alleles) whose presence/absence correlated with survival
by fitting Cox proportional hazards model [26] that computed the
p value for each allele testing the hypothesis that survival was
independent of the presence/absence of that allele. This backward
elimination method was used for feature selection in the
multivariate Cox proportional hazard model. A prognostic index
for each patient was calculated as the weighted average (weighted
as regression coefficient) of the variables selected for the
multivariate Cox model. A high value of the prognostic index
corresponded to a high hazard of death, and consequently a poor
predicted survival. The patients were classified into high risk or
low risk groups based on whether their prognostic index was above
or below the median.
Leave-One-Out-Cross-Validation (LOOCV) was applied to
evaluate the predictive accuracy of survival risk classifiers based
on high-dimensional data [27]. A single event (patient) was
omitted and the entire procedure described above was performed
to create a prognostic index. This function was created from
scratch on the training set with the one case removed, including
the feature selection step in the multivariate Cox model. Having
determined a prognostic index function for that training set, this
was used to compute a prognostic index for the omitted event.
That observed value was compared to the prediction of the
prognostic index for the n-1 cases included in that training set. The
omitted patient was placed into either a high risk group or a low
risk group based on his/her prognostic index . = or , the
median of the prognostic index in the training set. This analysis
was repeated from scratch n times, leaving out a different patient
each time.
Kaplan-Meier survival curves were plotted for the cases
predicted to bear above or below average risk as for the above
model. Since the risk group for each case was determined based on
a predictor that did not use that case in its construction, the
Kaplan-Meier curves were unbiased and the separation between
the curves gave a fair representation of the predictive value of
genotyping profiles on survival.
Next, we tested whether the association of genotyping with
survival was statistically significant. A log-rank statistic (LRd) was
computed for the cross-validated Kaplan-Meier curves. We
performed a statistical significance test by randomly shuffling
survival data among the cases and repeating the entire cross-
validation process. For each random re-shuffling, we repeated the
process, created new cross-validated Kaplan-Meier curves, and
computed the log-rank statistic for the random shuffling, which
served as a null-distribution of the log-rank statistic created in this
way. We defined the tail area of this null distribution beyond the
value LRd obtained for the real data as the permutation
significance level for testing the null hypothesis that there was no
relation between the genotyping data and survival.
We then compared the combined survival risk model (i.e.,
genotyping + covariate) to the model based only on the covariate
(i.e., stage) using as a test statistic the difference between the cross-
validated log-rank statistic for the combined model minus the log-
rank statistic for cross-validated Kaplan–Meier curves for the
covariate model. The null distribution of the test statistic was
generated based on permuting the genotyping vectors among
cases. In these permutations, the correspondence between survival
times, censoring indicators and the covariate were not disrupted.
The null hypothesis tested was that the genotyping data were
independent of survival and the covariate. This approach is
described more fully in R Simon et al. [27].
We finally evaluated if the survival risk model built on OS data
can be used to predict RFS. LOOCV was performed by building
the survival risk model on the training set OS data but validating
the model on the test set RFS data.
Considering the arbitrary cut-off percentiles specified for
defining the risk groups (50th percentile cut-off was used in our
case), we created a time-dependent ROC curve from censored
survival data [28], indicating how well the marker predicted the
survival time for the subjects in the dataset by TP (True Positive),
FP (False Positive), AUC (Area Under (ROC) Curve) at the time
point of interest (e.g., 7 year survival).
Table 1. PCR Primers for FOXP3 (TC)n amplification.
SNP name Forward Reverse
CT 318 59-ACCCTTGTACTCCAGGAAATTCTC 59-Biotin-GGTTTAGCTGTTACGTCGAAAAGA
AG 49 59-TTTCAGCGGCACAAGGCTC 59-Biotin-GAGTGCAGGGCCAGGTCC
CT 60 59-GCAAGTCATTCTTGGAAGGTATC 59-Biotin-TGCCAATTGATTTATAAAGGACTG
JO 27 59-GAGCTGGTCAGCCGAGAT 59-Biotin-TGACACCACCCCTCCATAAT
JO 30 59-CAAAGCAAAACGCTGCCAATAA 59-Biotin-TCCAGTGGCAATAGGAGCTTTC
JO 31 59-TTGTCATGTTAGCCGTGCAGC 59-Biotin-CCACCACCACACCCAGGTAA
(TC)n 59-FAM-TCCACTGTTCCCAAAGTTCTAGC 59GAGTGCTGGAGATAATGTTGGAAGT
doi:10.1371/journal.pone.0040805.t001
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Results
Individual Genotyping Markers Predict OS and RFS of
Patients with Melanoma Receiving Adjuvant IFN-a
Therapy
Univariate survival analysis suggested that patients bearing
either the DRB1*15 or HLA-Cw7 allele suffered worse OS while
patients bearing either HLA-Cw6 or HLA-B44 enjoyed better OS.
DRB1*15 positive patients suffered also worse RFS and conversely
HLA-Cw6 positive patients had better RFS. The p values, Hazard
Ratio (HR), and 95% Confidence Interval (CI) of HR for the
significant markers (Wald test p value ,0.05) are listed in Table 2
and Table 3, for OS and RFS, respectively. Kaplan-Meier curves
for DRB1*15 are shown in Figure 1A and 1B for OS (log rank p
value = 0.027) and RFS (log rank p value = 0.025), respectively.
Comparison of FOXP3 microsatellites did not demonstrate
significant associations (Univariate survival analysis for FoxP3
microsatellites, Table S1) and, therefore, the final data presented
here using a model excluded FOXP3 from the analysis. We would
however emphasize that this results should not exclude completely
lack of association between FOXP3 genetic variants and outcome
of IFN-a therapy as other SNPs not analyzed in this study could
have provided different information. Such analysis is the subject of
future studies.
A Five-marker Genotyping Signature has Prognostic
Significance on OS of Patients with Melanoma Receiving
Adjuvant Therapy with IFN-a
Multivariate analysis revealed that a five-marker genotyping
signature was prognostic of OS. In the final multivariate Cox
regression model, HLA-B38 (p = 0.021), HLA-C15 (p = 0.025),
HLA-C3 (p = 0.014), DRB1*15 (p = 0.005) and CT60*G/G
(0.081) (Table 3) were significantly associated with OS with risk
ratio of 0.097 (95% CI, 0.013 to 0.709), 0.387 (95% CI, 0.169 to
0.889), 0.449 (95% CI, 0.237 to 0.851), 1.948 (95% CI, 1.221 to
3.109) and 1.484 (95% IC, 0.953 to 2.312) respectively (Table 4).
A prognostic index for a patient with a specific genotyping profile
could be calculated as the weighted average (weighted as
regression coefficient) of the above five variables.
LOOCV Kaplan-Meier curve (Figure 2 A) identified 90 patients
(22 deaths) in the low risk group and 194 (78 deaths) in the high
risk group. The median OS of the low risk group has not yet been
reached, while it was 68.2 months in the high risk group (log rank
test p = 0.0026). The permutation p-value was 0.04 (500 permu-
tations) indicating that the association of genotyping with OS was
statistically significant. Time-dependent ROC curves showed that
the AUCs at 5 and 7 year were 0.645 and 0.72, respectively
(Figure 2B, 7 year survival ROC curve).
A Five-marker Genotyping Signature is an Independent
Predictor of OS Independent of Disease Stage
To assess whether the prediction of OS by the five marker
signature was affected by stage of disease, multivariate Cox
regression analysis was performed by adding stage as a factor.
Hazard ratios (HR), 95% CI of HR, and p values are shown for
the five markers and disease stage (Table 5).
LOOCV Kaplan-Meier curve (Figure 3A) showed that 131
patients (31 deaths) were in the low risk group and 153 patients (69
deaths) were in the high risk group. The median OS of the low risk
group had not yet been reached, while it was 64.3 months in the
high risk group (log rank test p = 0.00009). The permutation
significance level was 0.05 (500 permutations), indicating that the
association of genotyping data with OS data was statistically
significant. Time-dependent ROC curve showed that the AUC for
7 year survival was 0.735. This, the five-marker genotyping
signature was an independent predictor of OS after controlling for
disease stage (Figure 3B) while stage of disease was an independent
risk factor (Table 3).
A Five-marker Genotyping Signature may be Used as a
Prognostic Index for RFS in Patients with Melanoma
Receiving Adjuvant IFN-a Treatment
We attempted to build the RFS model using an approach
similar to the OS model. However, Kaplan-Meier plot obtained
from LOOCV did not show a clear separation between the curves,
indicating a poor performance of the model in predicting RFS risk.
We then evaluated the five-marker OS model on RFS survival
data. LOOCV was performed as predictive of OS but then was
tested on RFS survival data. The LOOCV Kaplan-Meier curve
demonstrated that 90 patients (44 relapses) were in the low risk
group (median RFS: 36.7 months) and 194 patients (111 relapses)
were in the high risk group (median RFS: 63.0 months) (log rank
test p = 0.048) (Figure 4A). The permutation significance level was
0.09 (1,000 permutations), indicating the association of genotyping
data to RFS data was borderline statistically significant.
We finally evaluated if the combined survival risk model, i.e.,
genotyping + stage model built on OS data, can also be used to
predict RFS. The Leave-One-Out Cross Validated Kaplan-Meier
curve is shown in Figure 4B, with 131 patients (60 relapses) in the
low risk group (median RFS 29.9 months) and 153 patients (95
relapses) in the high risk group (median RFS 65.3 months) (log
rank test p = 0.001). The permutation significance level was 0.06
(500 permutations), indicating the association of genotyping data
and stage to RFS data was borderline statistically significant.
Discussion
In the past decade, great efforts have been dedicated to identify
and validate prognostic markers in patients with advanced
melanoma. Such markers could assist the selection by physicians
of the most suitable treatments on a patient-specific basis. In the
case of IFN-a therapy, although robust predictors of response to
therapy have not yet been identified weak prognostic associations
Table 2. Univariate overall survival (OS) analysis.
Variables P value HR 95% CI of HR
DRB1*15 0.028 1.676 [1.056, 2.659]
Cw6 0.029 0.510 [0.279, 0.933]
Cw7 0.030 1.547 [1.044, 2.291]
B44 0.040 0.421 [0.184, 0.961]
doi:10.1371/journal.pone.0040805.t002
Table 3. Univariate relapse free survival (RFS) analysis.
Variables P value HR 95% CI of HR
Cw6 0.021 0.593 [0.380, 0.924]
DRB1*15 0.026 1.543 [1.054, 2.260]
doi:10.1371/journal.pone.0040805.t003
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have previously been described [29]. Recently, increased infiltra-
tion of lymphocytes within tumors was recognized to bear positive
predictive value and correlate with good prognosis in patients with
various cancer types independent of treatment suggesting an
important role of the adaptive immune response in controlling
disease progression [30–33]. This may in turn bear predictive and
prognostic significance in patients with melanoma treated with
IFN-a as this cytokine is believed to exerts its effects at least in part
through activation of T cells within the tumor microenvironment
[34]. Therefore, polymorphism of genes involved in the modula-
tion of T cell function could play important role in promoting or
inhibiting cancer progression. It has been reported that IFN-c
(+874A–T) polymorphism is significantly associated with RFS and
OS of patients with melanoma. Combined with two weakly or
marginally associated polymorphisms of IL10 and ERCC1,
patients could be stratified into distinct groups with different
clinical outcomes [35]. Furthermore, polymorphism of CCR5, a
chemokine receptor preferentially expressed by Th1 T cells and
responsible for homing to the site of inflammation via interaction
with its ligands has been reported to have clinical relevance; the
D32 deletion of CCR5 was reported to be associated with
decreased survival in patients with melanoma receiving immuno-
therapy [36]. A combination of three polymorphism of CDKN2A
spanning the coding exon 1a (rs2811710), the first intron
(rs2518720), and the 59 regulatory region (rs2811708) was also
reported significantly associated with decreased OS in melanoma
[37].
In the current study, CTLA4, FOXP3 and HLA were selected
because T lymphocytes play a major role both in tumor immunity
and autoimmunity and these genes are well known to directly or
indirectly affect T cell function. CD28, CTLA4 and inducible co-
stimulator (ICOS) molecules are key secondary signal molecules in
T lymphocyte activation. SNPs in the CD28/CTLA4/ICOS gene
region were reported to be associated with several autoimmune
diseases including, type-1 diabetes, systemic lupus erythematosus,
autoimmune thyroid diseases and celiac disease [11,20,38]. High
expression of FOXP3 in CD4+ and CD25+ T helper cells is
indicative of immune suppressive function [39,40]. However,
recent publications indicate that increased FOXP3 expression in
CD8+ T cell serves as a good prognosis marker in melanoma
patients undergoing high does IL-2 combined with peptide
vaccination therapy [41]. We observed that FOXP3 gene up
regulation in tumor infiltrating lymphocytes expanded in vitro for
adopted transfer therapy is associated with likelihood of response
to therapy (unpublished observation). Correlation of HLA
phenotypes with clinical outcome have been studied in infectious
disease, transplantation rejection, disease susceptibility and prog-
nosis of cancer [42].
Previously, we reported that RFS and OS did not differ
significantly between patients with distinct CTLA4 polymorphisms
when assessed alone [12]. Similarly, individual HLA class I and II
alleles were not informative in predicting recurrence in patients
receiving adjuvant IFN-a with the exception of HLA-Cw*06
which was associated with a better RFS and OS [43]. In the
current analysis, we found that patients carrying either DRB1*15
or HLA-Cw7 suffered worse OS while patients with either HLA-
Figure 1. Kaplan-Meier curves for DRB1*15 for OS and RFS. The Leave-One-Out Cross Validated (LOOCV) Kaplan-Meier curves to compare
DRB1*15 positive (red line) and negative patients (green line) for OS (log rank p value = 0.027) (Figure 1A) and RFS (log rank p value= 0.025)
(Figure 1B), respectively.
doi:10.1371/journal.pone.0040805.g001
Table 4. Multivariate overall survival (OS) analysis.
Alleles HR 95% CI of HR P value
HLA-B38 0.097 [0.013, 0.709] 0.021
HLA-C15 0.387 [0.169, 0.889] 0.025
HLA-C3 0.449 [0.237, 0.851] 0.014
DRB1*15 1.948 [1.221, 3.109] 0.005
CT60*G/G 1.484 [0.953, 2.312] 0.081
doi:10.1371/journal.pone.0040805.t004
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Cw6 or HLA-B44 had better OS. However, only Cw6 and
DRB1*15 could inversely predict RFS (p= 0.021, HR 0.593 and
p= 0.026, 1.543 respectively).
As high throughput and high resolution technologies are applied
in human study, increasing evidence suggests that a given immune
physiological and pathological condition is regulated and governed
by coordinated gene networks and overlapping pathways [44–46].
Million years of evolution and selection acquired redundant
machineries to compensate for single allele variants such as
synonymous polymorphism or silent mutation that alone would
impact of critical functions. This may have resulted in not one
single gene playing a high weight in determining the fate of
complex diseases, but rather a combination of modifiers affecting a
giving phenotype. Thus, multigenic correlations are more likely to
be effective in predicting patient outcomes [47,48]. In this study,
the association of SNPs in the CTLA4, microsatellite in FOXP3
and HLA genotype taken as single factors has marginal bearing on
survival risk. However, the analytic strategy based on Cox’s
proportional hazards model identified a combination that had
predictive value on clinical outcome: HLA-B38, HLA-C15, HLA-
Cw3, DRB1*15 and CTLA4 CT60*G/G gene polymorphisms.
Among the five identified markers, HLA-B38, HLA-C15 and
HLA-C3 were associated with low risk of RFS. HLA-B38
previously had been positively associated with several autoimmune
disorders [49] and negatively with childhood acute leukemia [50].
HLA-Cw3 has been reported as a favorable prognostic
biomarker. In a prospective randomized, observation-controlled,
phase III trial of adjuvant Melacine as allogeneic stage IV
melanoma vaccine study, patients expressing $2 specific class I
antigens (HLA-A2, HLA-A28, HLAB44, HLA-B45 and HLA-C3)
and carrying HLA-Cw3 and/or HLA-A2 genotype enjoyed
significant benefit from adjuvant therapy (5-year RFS for
vaccinated patients was 77%, compared with 64% in the
observation group, P= 0.004) [51].
Conversely, the DRB1*15 allele was found to be a high risk
marker in our prediction model. DRB1*15 is one of the
susceptibility factors for multiple sclerosis [52] and DRB1*15
alleles is associated with significantly increased risk to develop
hepatocellular carcinoma in Asians (OR=2.88, 95%CI: 1.77–
4.69, P,0.001) [53]. The DRB1*15-DQB1*06 haplotype is also
associated with predisposition to suffer HPV infection (p(c) ,0.05)
and develop cervical cancer (p(c) ,0.05) [54] suggesting that this
genotype is associated with malignance predisposition.
In addition to HLA, CT 60 G/G allele, one of the CTLA4
polymorphisms was identified as a high risk markers in this
multivariate analysis associated with shorter OS. CTLA4
polymorphism has been reported in association with degree of
responsiveness in melanoma patient treated by CTL-4 blockade
Figure 2. LOOCV Kaplan-Meier and Time-dependent ROC curves. A prognostic index for a patient with a specific genotyping profile were
calculated as the weighted average (weighted as regression coefficient) of the five-marker genotypes. LOOCV Kaplan-Meier curve (Figure 2 A)
identified 90 patients (22 deaths) in the low risk group (green line) and 194 (78 deaths) in the high risk group (red line). Time-dependent ROC curves
showed that the AUCs at 5 and 7 year were 0.645 and 0.720, respectively (Figure 2B, 7 year survival ROC curve).
doi:10.1371/journal.pone.0040805.g002
Table 5. Multivariate overall survival (OS) analysis with stage
correction.
Alleles HR 95% CI of HR P value
HLA-B38 0.089 [0.012, 0.648] 0.017
HLA-C15 0.443 [0.192, 1.020] 0.056
HLA-C3 0.446 [0.235, 0.847] 0.014
DRB1*15 1.729 [1.078, 2.773] 0.023
CT60*G/G 1.715 [1.093, 2.691] 0.019
Stage 2.062 [1.314, 3.234] 0.002
doi:10.1371/journal.pone.0040805.t005
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Figure 3. Multivariate Cox regression analysis with stage as a factor. LOOCV Kaplan-Meier curve (Figure 3A) showed that 131 patients (31
deaths) were in the low risk group (green line) and 153 patients (69 deaths) were in the high risk group (red line). The Leave-One-Out Cross Validated
time dependent (7 year) ROC curves (Figure 3B) to compare different prognostic models: Stage only (dashed line); Stage and five-marker genotyping
signature (red line); Five-marker genotyping signature only (green line).
doi:10.1371/journal.pone.0040805.g003
Figure 4. The LOOV Validated Kaplan-Meier curve based on combined survival risk model. The LOOCV Kaplan-Meier curves showed that
the five-marker OS model (Figure 4A) and the combined model (five-marker + stage model) (Figure 4B) may be used to predict RFS survival data. In
each round of LOOCV, the model was built in the training set using the OS information and tested on the left out sample using the RFS information.
doi:10.1371/journal.pone.0040805.g004
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[55]. CTLA4 haplotypes has also been documented in association
with susceptibility to develop esophageal squamous cell carcinoma
and osteosarcoma [56,57]. However, no significant association
between CT 60 G/G allele and with risk of developing cancer has
been previously reported (CT60: OR, 1.02; 95% CI, 0.80–1.29 for
AA + AG vs GG) based on 48 case-control meta analysis studies
from 27 articles were analyzed [58].
Conclusion
Our study suggests that single nucleotide variants and their
association with a given condition should be explored together
with polymorphisms genes with relevant and compensatory
function that are thought to contribute to biological changes.
Genome wide association analysis would be an ideal way to
explore the complexity of genetic variants associated with disease
predisposition, prognosis and treatment response, if patient
population and funding issue is not challenged. The five markers
identified in the study need to be validated prospectively in an
independent cohort of patients receiving the same therapy.
Moreover, all patients underwent IFNa treatment following
excision of the melanoma but had different survival outcomes;
thus, the study was aimed at testing the genetic bearing within the
cancer population on clinical outcome. A population not
undergoing this treatment is currently not available to these
investigators and, therefore, this study cannot conclusively address
the issue of whether the combination of genetic markers is
predictive or response to therapy rather than reflecting an overall
genetic predisposition to better prognosis.
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